Navigation Links
Synthetic Biologics Reports Third Quarter 2012 Financial Results
Date:11/14/2012

™ and LEAP™ are registered trademarks of Intrexon Corporation.

This release includes forward-looking statements on Synthetic Biologics' current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our continued focus of our efforts in the field of synthetic biology and advancing our clinical programs and the expected size of the future market for sales of therapies for CDI and Acinetobacter. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Synthetic Biologics' forward-looking statements include, among others, a failure to receive the necessary regulatory approvals for commercialization of our therapeutics, a failure of our clinical trials to be commenced or completed on time or to achieve desired results, a failure of our clinical trials to receive anticipated funding, a failure of gene therapy to receive market acceptance, a failure of our monoclonal antibodies for the treatment of infectious diseases to be successfully developed or commercialized, our inability to maintain our licensing agreements, including our agreement with Intrexon, our inability to successfully integrate new management, or a failure by us or our strategic partners to successfully commercialize products and other factors described in Synthetic Biologics' report on Form 10-K/A for the year ended December 31, 2011 and any other
'/>"/>

SOURCE Synthetic Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Synthetic Biologics to Acquire Clinical-Stage C. difficile Infectious Disease Program
2. Taming mavericks: Stanford researchers use synthetic magnetism to control light
3. Synthetic Biologics Completes $10.8 Million Private Placement Financing
4. Synthetic Biologics Announces $10.8 Million Financing
5. Synthetic Genomics Inc. Purchases Patent Portfolio from Febit Holding GmbH
6. Synthetic Biology Market is Expected to Reach USD 16.7 Billion Globally in 2018: Transparency Market Research
7. Synthetic Biologics and Intrexon Corporation Enter Worldwide Exclusive Collaboration for Infectious Diseases
8. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
9. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
10. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
11. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimestaâ„¢ for Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: RP), ... development of autologous cell therapies, announced today the publication ... in conjunction with co-authors from Kyoto University and the ... ongoing clinical research using dermal sheath cup (DSC) cells ... The paper entitled " Hair Follicle Dermal Stem Cells ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 ... peer-reviewed publication of original research, reviews and editorials ... and clinical practice, today published a provocative article ... the development, progression and potential treatment of prostate ... endocrinology research and proposes the possibility that there ...
(Date:12/19/2014)... Charm Sciences is pleased to announce that ... Aflatoxin M1 in raw commingled milk is the first ... The peer reviewed report of the validation by Technology ... and Fisheries Research (ILVO-T&V) has been published by the ... most toxic aflatoxin and a known carcinogen, can be ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2
... , SAN DIEGO, June 8 , , ... 51 speakers and panelists discussing life sciences and the business relationships ... WHAT: , CALAsia is an international 2-day forum that ... and the Asia Pacific region to identify, explore, and further trans-Pacific ...
... on Testing OVAR Effectiveness , , PITTSBURGH, June ... ), manufacturers of noninvasive medical evaluation equipment used ... disorders, said today that the University of Michigan ... has purchased and installed its I-Portal(R) NOTC (Neuro-Otologic Test ...
... 8 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA ... that it,begins the production of a vaccine against influenza A (H1N1) ... to the company on June 8, 2009. , ... ,In,the midst of a global outbreak and transmission of H1N1, our ...
Cached Biology Technology:BIOCOM's Inaugural CALAsia Forum 'Bridging the Pacific' 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 2University of Michigan Installs Neuro Kinetics' I-Portal(R) NOTC System 3Sinovac Begins the Production of Influenza A (H1N1) Vaccine 2Sinovac Begins the Production of Influenza A (H1N1) Vaccine 3
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:11/21/2014)... 2014 According to a new ... (Video, RFID, Access Control, Intrusion Detection, Parking Management, Under ... Component Service Geography - Global Forecasts to 2020", published ... to be around $25 Billion in 2014 and is ... a CAGR of 8.69%. Browse 116 market ...
(Date:11/18/2014)... 18, 2014  The Secure Identity & Biometrics ... jointly announce the formation of The Airport Entry ... Identity and Biometric Entry and Exit Solutions ... official support from BORDERPOL, the international non-profit organization ... provide expertise regarding border security, traveler and migration ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3
... cracked a 35-year-old mystery about the workings of the natural ... futuristic genre of synthetic nanomotors that pump therapeutic DNA, RNA ... innermost mechanisms of these nanomotors in a bacteria-killing virus ... is being published online today in the journal ACS ...
... age who go on to develop autism are slower to ... when compared to 7-month-olds who do not develop autism, and ... circuits. Those are the findings of a new study ... and published online March 20 by the American Journal ...
... Society for Microbiology (ASM) will hold its 113th ... The meeting will feature approximately 3,000 individual ... has an expected attendance of 8,000. Microbiologists ... work is critical to human and animal health, ...
Cached Biology News:Atypical brain circuits may cause slower gaze shifting in infants who later develop autism 2American Society for Microbiology to host 113th General Meeting in Denver 2
Mouse VEGF R1/Flt-1 Allophycocyanin MAb (Clone 141522) Keywords: Receptor Tyrosine Kinase, RTK, VEGFR1, VEGF Receptor 1 Protein Family: Receptor Tyrosine Kinases, VEGF/PDGF Family...
Evi-1 Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Immunogen: Synthetic peptide: N(171) H G F L S A D Q QL I K(183) Storage: -20 C, Avoid Freeze/Thaw Cycles...
HIV-1 TAT (vN-21)...
Biology Products: